论文部分内容阅读
为了证实溴隐亭对帕金森氏病伴高血压病患者的降压效果并探讨其作用机制,作者对10名原发性帕金森氏病伴高血压病(舒张压>95mmHg)患者分为两组进行对照研究。第一组(试验组):5例,其中男2例,女3例,平均年龄为69.8±2.7岁。3例未作任何治疗,2例已服左旋多巴(1000mg/日)及多巴脱羧酶抑制剂6个月,血压无变化。试验前平均血压,卧位194.0±2.4/104.0±4.0mmHg,立位202.5±7.5/112.5±7.5mmHg;平均心率:卧位80.0±1.2/分,立位81.0±1.0/分。全组均以溴隐亭治疗12个月,剂量第一日为2.5mg,以后每日增加2.5mg,直到最适合的治疗量,平均为56.0±12.9mg/日(20～90mg/日),分三次服。全组均在3个月后加服domperidone(周围性多巴胺能拮抗剂,可减轻溴隐亭的催吐付作
In order to confirm the antihypertensive effects of bromocriptine on patients with Parkinson’s disease and its mechanism of action, we divided the 10 patients with primary Parkinson’s disease with hypertension (diastolic blood pressure> 95mmHg) into two Group control study. The first group (experimental group): 5 cases, including 2 males and 3 females, with an average age of 69.8 ± 2.7 years. No treatment was given in 3 cases, 2 cases had taken levodopa (1000mg / day) and dopa decarboxylase inhibitor for 6 months, no change in blood pressure. The mean blood pressure before the test was 194.0 ± 2.4 / 104.0 ± 4.0 mmHg in the supine position and 202.5 ± 7.5 / 112.5 ± 7.5 mmHg in the standing position. The average heart rate was 80.0 ± 1.2 / d in the lying position and 81.0 ± 1.0 / d in the standing position. The whole group were treated with bromocriptine for 12 months, the first dose of 2.5mg, the daily increase of 2.5mg, until the most appropriate amount of treatment, with an average of 56.0 ± 12.9mg / day (20 ~ 90mg / day) Sub-three service. The whole group in 3 months after adding domperidone (peripheral dopaminergic antagonists, can reduce the bromocriptine emetic pay for